BioCentury
ARTICLE | Clinical News

SU101 platelet-derived growth factor receptor inhibitor: SUGN enrolling patients who have had surgery or radiation thereapy and chemotherapy

September 21, 1998 7:00 AM UTC

Sugen Inc. (SUGN), Redwood City, Calif. Product: SU101 platelet-derived growth factor receptor inhibitor Indication: Treat non-small cell lung cancer Status: SUGN will enroll up to 30 patients who hav...